Pure Global
NCT06400719

Pilot Study of AVT16 in Healthy Adult Subjects

An Open Label, Single Arm Pilot Study to Investigate the Safety and Tolerability of a Single 300mg Intravenous Dose of AVT16 in Healthy Adult Subjects Aged 18 to 55 Years Inclusive
Alvotech Swiss AG·Phase 1·ClinicalTrials.gov·biologicalNot yet recruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Healthy
Drug/Device/Intervention
AVT16
Study type
Interventional
Intervention type
biological
Sponsor & location
Primary sponsor
Alvotech Swiss AG
Location
Christchurch, New Zealand
Timeline & enrollment
Phase
Phase 1
Start date
May 15, 2024
End date
Oct 16, 2024
Enrollment
18 participants
Primary outcome

Incidence, nature and severity of Treatment Emergent Adverse Events

Summary

This is a pilot study in healthy adult subjects to evaluate the safety and tolerability of
 AVT16 after administration of a single intravenous administration. Pharmacokinetics and
 immunogenicity of AVT16 will also be evaluated.

ICD-10 classifications
ObesitySeeking and accepting physical, nutritional and chemical interventions known to be hazardous and harmfulHealthy person accompanying sick personLifestyle-related conditionMalnutrition
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06400719
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06400719 through Pure Global AI's free database. This Phase 1 trial is sponsored by Alvotech Swiss AG and is currently Not yet recruiting. The study focuses on Healthy. Target enrollment is 18 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.